Next generation CDK4 + CDK2 selective inhibitor in HR+ HER2- metastatic breast cancer
Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase Ib/II dose-escalation study (NCT05262400) of PF-07220060 (CDK4-selective inhibitor) and PF-07104091 (CDK2-selective inhibitor) in HR+ HER2- metastatic breast cancer and advanced solid tumors. The combination demonstrated promising antitumor activity in heavily pretreated patients, particularly in those with ESR1 mutations. Common adverse events included neutropenia, nausea, and diarrhea, and dose expansion is ongoing. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.